Abivax
ABVX
43 hedge funds and large institutions have $235M invested in Abivax in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 9 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
18% more capital invested
Capital invested by funds: $199M → $235M (+$36.1M)
1.76% less ownership
Funds ownership: 50.08% → 48.33% (-1.8%)
7% less funds holding
Funds holding: 46 → 43 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$5.61M |
| 2 |
CP
Caligan Partners
New York
|
+$2.64M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$1.95M |
| 4 |
Millennium Management
New York
|
+$1.72M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$903K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Allostery Investments
Stamford,
Connecticut
|
-$6.08M |
| 2 |
JP Morgan Chase
New York
|
-$5.67M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.66M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.26M |
| 5 |
Walleye Capital
New York
|
-$1.38M |
ABVX Hedge Fund Activity: Q2 2025 in Review
43 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q2 2025, worth a combined $235M — up 18% from $199M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ABVX and 6 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 16 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $5.61M. The largest seller was Allostery Investments, cutting an estimated $6.08M.
- 43 institutional investors held Abivax (ABVX) as of Q2 2025, down from 46 in Q1 2025.
- Funds reported $235M of Abivax stock for Q2 2025, up 18% quarter-over-quarter.
- 6 funds opened new Abivax positions in Q2 2025 and 9 closed out, a net change of -3 holders.
- The largest Abivax buyer in Q2 2025 was ADAR1 Capital Management, an estimated $5.61M added.
- The largest Abivax seller in Q2 2025 was Allostery Investments, an estimated $6.08M sold.
Based on aggregated 13F filings for Q2 2025.